Last reviewed · How we verify
KN057
KN057 is a monoclonal antibody that targets and blocks the OX40 receptor to enhance anti-tumor immune responses.
KN057 is a monoclonal antibody that targets and blocks the OX40 receptor to enhance anti-tumor immune responses. Used for Advanced or metastatic solid tumors (in combination with other immunotherapies).
At a glance
| Generic name | KN057 |
|---|---|
| Sponsor | Suzhou Alphamab Co., Ltd. |
| Drug class | OX40 agonist monoclonal antibody |
| Target | OX40 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
OX40 is a co-stimulatory molecule expressed on activated T cells that plays a critical role in T cell proliferation and survival. By agonizing OX40, KN057 enhances T cell activation and expansion, promoting anti-tumor immunity. This mechanism is designed to work synergistically with other immunotherapies to improve anti-tumor efficacy.
Approved indications
- Advanced or metastatic solid tumors (in combination with other immunotherapies)
Common side effects
- Immune-related adverse events (irAEs)
- Fatigue
- Infusion reactions
Key clinical trials
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors (PHASE3)
- Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors (PHASE3)
- KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (PHASE2)
- KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |